EXCEED ET is a study evaluating ropeginterferon alfa-2b-njft in the treatment of essential thrombocythemia. Learn if your patient is eligible today.

2023年5月31日 · Background: Essential thrombocythemia (ET) is a myeloproliferative neoplasm (MPN) characterized by a high platelet count due to an overacting JAK-STAT pathway as a result of the most common mutations in JAK2, CALR and MPL genes. There is a high, unmet clinical need for safe and effective treatment options for patients with ET who require ...

星途品牌成立于2019年，是奇瑞集团高端品牌。 致力于以超越精神为引领 ，为全球新中产家庭带来现代豪华、全域智能、极致驾乘的划时代产品，成为全球热爱的科技新豪华品牌。

2025年1月6日 · In addition to SURPASS-ET, ropeginterferon alfa-2b is undergoing evaluation in the phase 2b EXCEED-ET (NCT05482971) trial in North America for patients with ET. The single-arm, multicenter trial aims to evaluate the agent’s efficacy, safety, and tolerability in adult patients with ET, with data from the trial expected in the second half of 2025.

Do you have essential thrombocythemia (ET)? You may be eligible to join EXCEED ET, a Phase 2b clinical research study in the US and Canada that evaluates the potential of a new, investigational ET therapy to control the number of platelets and white blood cells in the blood. Find out if you are eligible

EXCEED-ET: A single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in North American adults with essential thrombocythemia.

2023年11月2日 · Lucia Masarova, MD, PhD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the rationale of the EXCEED-ET study (NCT05482971) of ropeginterferon alfa-2b-njf (Besremi) for patients with essential thrombocytopenia (ET).

EXCEED-ET: A single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in North American adults with essential thrombocythemia. Author Lucia Masarova, John Mascarenhas, Albert Qin, Weichung Shih, Toshiaki Sato, Raymond Urbanski, Oleh Zagrijtschuk, and Craig Zimmerman

The objective of this study is to assess the efficacy of ropeginterferon alfa-2b-njft, a new generation interferon alfa, in adults with ET who live in the US or Canada. Methods: This single-arm, open-label study includes a 28-day screening period, a 12-month treatment phase, and a 28-day follow-up period, for a total trial duration of 14 months.

2023年7月16日 · Ropeginterferon alfa-2b-njf (Besremi) is a next-generation interferon alfa agent. It is FDA-approved to treat another myeloproliferative neoplasm (MPN), polycythemia vera (PV). In ET, ropeginterferon alfa-2b-njf is being investigated for the treatment of adult patients in a single-arm, multicenter trial (EXCEED-ET; NCT05482971).